MedTrace Logo

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 347

Last updated 2019-07-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.

Conditions

Interventions

BIOLOGICAL

Albumin 5%

Therapeutic plasma exchange with human albumin 5%

BIOLOGICAL

Albumin 20%

Low volume plasma exchange with human albumin 5%

BIOLOGICAL

Immunoglobulin

Intravenous human immunoglobulin 5%

Sponsors & Collaborators

  • Grifols Biologicals, LLC

    collaborator INDUSTRY

  • Instituto Grifols, S.A.

    lead INDUSTRY

Principal Investigators

  • Merce Boada Rovira, MD, PhD · Fundació ACE. Barcelona. Spain

  • Antonio Páez, MD · Instituto Grifols, S.A.

  • Laura Núñez, BSc · Instituto Grifols, S.A.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-19
Primary Completion
2018-03-06
Completion
2018-03-06

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01561053 on ClinicalTrials.gov